Drug Delivery Business News

"I feel good about Libre, our U.S. position and the momentum we’re going to have internationally." On Abbott's third-quarter earnings call, CEO Robert B. Ford talked Libre, the new dual sensor and more from the Abbott Diabetes Care business that continues to contribute significant growth within the company's Medical Devices segment. Full story at Drug Delivery Business News: https://lnkd.in/e4xqiyxM #medtech #medicaldevices #diabetes #earnings #sensors #CGMs #glucose #continuousglucosemonitor #ketones

“Today’s milestone brings us one step closer to offering young children and teenagers living with diabetes a potential alternative therapy to multiple daily injections or an insulin pump system." MannKind said the FDA accepted a supplemental biologics license for its Afrezza inhaled insulin. The submission, if ultimately approved, would enable MannKind to bring Afrezza to children and adolescents (aged 4-17). Full story here: https://lnkd.in/ei83hqHj #medtech #medicaldevices #diabetes #drugdelivery #insulin #insulindelivery #pharma #pharmaceutical

Subscribe to DDBN for your bi-monthly recap of the latest #DrugDelivery trends & research news. Get updates on #diabetes-care devices, drug-eluting stents, auto-injectors, & more: https://lnkd.in/eDg6MyEr

“As insulin pumps become increasingly automated and diabetes devices are worn longer on the body, the need to ensure accurate insulin delivery is now more important than ever. Our work aligns directly with DEKA, and we share a common mission to make insulin delivery safer and more reliable." DEKA, the firm developed the underlying drug delivery technology for hte Sequel Med Tech twiist automated insulin delivery system, has acquired the core assets and IP of Diatech Diabetes, a developer of technology aiming to improve the safety of insulin infusion for people living with diabetes. Full story here: https://lnkd.in/e9kxVgce #medtech #medicaldevices #diabetes #insulin #insulindelivery #insulinpumps

“Our product absolutely relies on taking advantage of where the world of AI is going,” Insulet CEO Ashley McEvoy says. At The MedTech Conference, she explained the automated insulin delivery system maker's approach to AI across the company and how the technology could play a role in changing human behavior in #diabetes management. More at Drug Delivery Business News: https://lnkd.in/eskbJ5Gv #medtech #medicaldevices #insulin #automatedinsulindelivery #insulinpumps #AI #artificialintelligence #MTC2025

“The ongoing investments we are making in our DTC marketing campaigns are accelerating awareness with patients and clinicians leading to the continued momentum behind Eversense. This is what encouraged us to bring the full sales and marketing organization in-house, giving us increased confidence in our ability to drive topline revenue and exceed patient expectations.” Senseonics reports preliminary third-quarter revenues that came in ahead of expectations on Wall Street and is conducting a 1-for-20 reverse stock split. Full story: https://lnkd.in/e8Bnd67i #medtech #medicaldevices #diabetes #CGM #glucose #continuousglucosemonitor

As Modular Medical prepares to advance its next-generation insulin patch pump through the regulatory processes, it has appointed a diabetes tech veteran to head up its international operations. David Bosshard joins with two decades of experience scaling similar tubeless insulin delivery systems across Europe and beyond. Read more here: https://lnkd.in/eRVknycG #medtech #medicaldevices #diabetes #insulin #insulinpumps

Now boarding the JetBlue #MedtechNerd flight to San Diego with Sean Whooley of MassDevice🛫🛫🛫🛫🛫 #devicetalkswest #MTC25 DeviceTalks AdvaMed See you fellow nerds soon!

Claims in a class action suit centered around the 2021 FDA warning letter issued to Medtronic's Diabetes business have been dismissed by a Minnesota judge. The lawsuit alleged that Medtronic officials at the time “engaged in deceptive conduct for the purpose of covering up severe product quality issues" related to the MiniMed 780G automated insulin delivery system. However, the judge found that the claims failed to meet the standards of securities fraud. Full story at Drug Delivery Business News: https://lnkd.in/easFTpRa #medtech #medicaldevices #diabetes #insulin #insulinpumps #automatedinsulindelivery

Dual sensors that continuously measure not only glucose, but ketone levels, too, could provide a huge boost in the management of diabetes. SiBionics says it has seen encouraging data supporting its effort on that front. Read about it here: https://lnkd.in/eYmitGuh #medtech #medicaldevices #sensors #CGM #continuousglucosemonitor #CKM #continuousketonemonitor #diabetes